TROV - TrovaGene, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.3211
-0.0057 (-1.7442%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close0.3268
Open0.3201
Bid0.3250 x 300
Ask0.3300 x 5000
Day's Range0.3201 - 0.3294
52 Week Range0.2400 - 1.6300
Volume535,922
Avg. Volume2,092,352
Market Cap17.754M
Beta-0.20
PE Ratio (TTM)N/A
EPS (TTM)-0.7200
Earnings DateMay 8, 2018 - May 14, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.50
Trade prices are not sourced from all markets
  • Trovagene Presents Data at AACR Meeting 2018 on Pharmacodynamic and Tumor Biomarkers During Treatment with PCM-075 and Low-Dose Cytarabine
    PR Newswire4 days ago

    Trovagene Presents Data at AACR Meeting 2018 on Pharmacodynamic and Tumor Biomarkers During Treatment with PCM-075 and Low-Dose Cytarabine

    Methodology to assess changes in leukemic cells, genomic alterations and pTCTP status for Phase 1b /2 Clinical Trial of PCM-075. Update on clinical trial recruitment. SAN DIEGO , April 17, 2018 /PRNewswire/ ...

  • Trovagene Presents Data at AACR Meeting 2018 Showing Synergy of PCM-075 in Combination with FLT3 Inhibitors in Acute Myeloid Leukemia (AML)
    PR Newswire5 days ago

    Trovagene Presents Data at AACR Meeting 2018 Showing Synergy of PCM-075 in Combination with FLT3 Inhibitors in Acute Myeloid Leukemia (AML)

    Combination of PCM-075, a highly-selective Polo-like Kinase 1 (PLK1) inhibitor, and Quizartinib resulted in 97% tumor growth inhibition and regression in FLT3 AML model SAN DIEGO , April 16, 2018 /PRNewswire/ ...

  • Trovagene Announces Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2018
    PR Newswire9 days ago

    Trovagene Announces Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2018

    SAN DIEGO , April 12, 2018 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a clinical-stage oncology therapeutics company, developing targeted therapeutics for the treatment of hematologic and solid tumor ...

  • Trovagene to Present at the 26th Annual Wall Street Investor Conference
    PR Newswirelast month

    Trovagene to Present at the 26th Annual Wall Street Investor Conference

    SAN DIEGO, March 20, 2018 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a clinical-stage precision medicine biotechnology company, developing targeted therapeutics to treat hematologic and solid tumor cancers, announced today that it will be presenting at The Wall Street Investor Forum 26th Annual Investor Conference in New York City at The University Club of NYC at 2:05 PM EDT / 11:05 AM PDT on Thursday, March 22, 2018. Bill Welch, Chief Executive Officer of Trovagene, will be presenting, as well as meeting with investors. Trovagene is a precision medicine biotechnology company developing oncology therapeutics for improved cancer care by leveraging its proprietary Precision Cancer Monitoring® (PCM) technology in tumor genomics.  Trovagene has broad intellectual property and proprietary technology to measure circulating tumor DNA (ctDNA) in urine and blood to identify and quantify clinically actionable markers for predicting response to cancer therapies.  Trovagene offers its PCM technology at its CLIA/CAP – accredited laboratory and plans to continue to vertically integrate its PCM technology with precision cancer therapeutics.  For more information, please visit https://www.trovagene.com.

  • Trovagene Announces First Patient Successfully Completes Cycle 1 of Treatment with PCM-075 in Combination with Low Dose Cytarabine (LDAC) in AML Trial
    PR Newswire2 months ago

    Trovagene Announces First Patient Successfully Completes Cycle 1 of Treatment with PCM-075 in Combination with Low Dose Cytarabine (LDAC) in AML Trial

    SAN DIEGO, March 5, 2018 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a precision medicine biotechnology company, developing targeted cancer therapeutics, today announced that the initial patient successfully completed the first cycle 1 of treatment in its Phase 1b/2 multicenter trial of PCM-075 in combination with low-dose cytarabine (LDAC) in patients with Acute Myeloid Leukemia (AML). The patient tolerated the combination well and correlative analyses of blood samples, taken at specified time points, also indicated activity on leukemic blood cells. A significant decrease in the percentage of blood leukemic cells was observed within 24 hours of administering PCM-075 + LDAC.

  • Associated Press2 months ago

    Trovagene reports 4Q loss

    On a per-share basis, the San Diego-based company said it had a loss of 6 cents. The molecular diagnostic company posted revenue of $185,000 in the period. For the year, the company reported that its loss ...

  • Trovagene Announces Fourth Quarter and Full-Year 2017 Results
    PR Newswire2 months ago

    Trovagene Announces Fourth Quarter and Full-Year 2017 Results

    SAN DIEGO , Feb. 26, 2018 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a clinical-stage precision medicine biotechnology company, developing targeted therapeutics to treat hematologic and solid tumor ...

  • Trovagene Announces Activation of Two Additional Clinical Trial Sites to Conduct its Phase 1b/2 Study of PCM-075 in Patients with AML
    PR Newswire2 months ago

    Trovagene Announces Activation of Two Additional Clinical Trial Sites to Conduct its Phase 1b/2 Study of PCM-075 in Patients with AML

    SAN DIEGO, Feb. 13, 2018 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a precision medicine biotechnology company, developing targeted oncology therapeutics, today announced the addition of two leading institutions, Yale Cancer Center and principal investigator Amer M. Zeidan, MBBS, MHS, and Kansas University Cancer Center and principal investigator Tara Lin, MD, to conduct its Phase 1b/2 open-label, multicenter trial of PCM-075 in patients with Acute Myeloid Leukemia (AML).

  • Trovagene Presents Data Showing Synergy of PCM-075 in Combination with Zytiga® in Castration-Resistant Prostate Cancer Model at 2018 Genitourinary Cancers Symposium
    PR Newswire2 months ago

    Trovagene Presents Data Showing Synergy of PCM-075 in Combination with Zytiga® in Castration-Resistant Prostate Cancer Model at 2018 Genitourinary Cancers Symposium

    Targeted treatment with highly-selective Polo-like Kinase 1 inhibitor PCM-075 in combination with Zytiga® (abiraterone acetate) may represent a new treatment option in CRPC SAN DIEGO , Feb. 9, 2018 /PRNewswire/ ...

  • Trovagene Announces Completion of Cycle-One Dosing in First Patient Enrolled in its Phase 1b/2 Clinical Trial of PCM-075 in Acute Myeloid Leukemia (AML)
    PR Newswire2 months ago

    Trovagene Announces Completion of Cycle-One Dosing in First Patient Enrolled in its Phase 1b/2 Clinical Trial of PCM-075 in Acute Myeloid Leukemia (AML)

    SAN DIEGO, Feb. 6, 2018 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a precision medicine biotechnology company, today announced that the first patient has completed the first cycle of dosing with PCM-075 in combination with low-dose cytarabine in its Phase 1b/2 multicenter trial of patients with Acute Myeloid Leukemia (AML). Two clinical trial sites are currently screening and enrolling patients and five additional sites are planned to be activated by the end of the first quarter. PCM-075 is the first oral PLK1-selective adenosine triphosphate competitive inhibitor to enter clinical trials with proven antitumor activity in hematologic and solid tumor preclinical models.

  • Who Owns Most Of TrovaGene Inc (NASDAQ:TROV)?
    Simply Wall St.3 months ago

    Who Owns Most Of TrovaGene Inc (NASDAQ:TROV)?

    In this analysis, my focus will be on developing a perspective on TrovaGene Inc’s (NASDAQ:TROV) latest ownership structure, a less discussed, but important factor. A company’s ownership structure is oftenRead More...

  • Trovagene Announces Initiation of UNITE Phase 2 Clinical Trial of PCM-075 in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
    PR Newswire3 months ago

    Trovagene Announces Initiation of UNITE Phase 2 Clinical Trial of PCM-075 in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)

    SAN DIEGO, Jan. 24, 2018 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a clinical-stage precision medicine biotechnology company, engaged in the development of targeted cancer therapies, today announced the initiation of its Phase 2 clinical trial, evaluating the combination of PCM-075 and abiraterone acetate (Zytiga® - Johnson & Johnson), in patients with metastatic Castration-Resistant Prostate Cancer (mCRPC). This clinical trial is called UNITE, "A Phase 2 Study to Understand the Novel Combination of PCM-075 and Abiraterone and the Opportunity to Improve Treatment and Extend Response in Patients with Metastatic Castration-Resistant Prostate Cancer." The study will enroll 25 patients with mCRPC who are showing early signs of disease progression while on abiraterone/prednisone therapy and will evaluate the proportion of patients achieving disease control after 12 weeks of study treatment.

  • Should You Be Concerned About TrovaGene Inc’s (NASDAQ:TROV) Risks?
    Simply Wall St.3 months ago

    Should You Be Concerned About TrovaGene Inc’s (NASDAQ:TROV) Risks?

    For TrovaGene Inc’s (NASDAQ:TROV) shareholders, and also potential investors in the stock, understanding how the stock’s risk and return characteristics can impact your portfolio is important. Every stock in theRead More...

  • Trovagene to Present at the Biotech Showcase™ Annual Conference
    PR Newswire4 months ago

    Trovagene to Present at the Biotech Showcase™ Annual Conference

    SAN DIEGO, Jan. 3, 2018 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), an oncology precision medicine biotechnology company, today announced that it will present at Biotech Showcase 2018 to be held January 8-10, at the Hilton San Francisco Union Square. Biotech Showcase™, produced by Demy-Colton and EBD Group, is an investor and networking conference devoted to providing private and public biotechnology and life science companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during the course of one of the industry's largest annual healthcare investor conferences, J.P. Morgan Annual Healthcare Conference.

  • Is Now The Time To Bet On The Healthcare Sector And TrovaGene Inc (NASDAQ:TROV)?
    Simply Wall St.4 months ago

    Is Now The Time To Bet On The Healthcare Sector And TrovaGene Inc (NASDAQ:TROV)?

    TrovaGene Inc (NASDAQ:TROV), a USD$16.23M small-cap, operates in the healthcare industry, which continues to be affected by the sustained economic uncertainty and structural trends, such as an aging population, impactingRead More...

  • Will TrovaGene Inc’s (NASDAQ:TROV) Earnings Grow In The Years Ahead?
    Simply Wall St.4 months ago

    Will TrovaGene Inc’s (NASDAQ:TROV) Earnings Grow In The Years Ahead?

    The latest earnings announcement TrovaGene Inc’s (NASDAQ:TROV) released in September 2017 signalled company earnings became less negative compared to the previous year’s level as a result of recent tailwinds InvestorsRead More...

  • Trovagene Announces Activation of Second Clinical Trial Site in Phase 1b/2 Acute Myeloid Leukemia (AML) Trial for PCM-075
    PR Newswire4 months ago

    Trovagene Announces Activation of Second Clinical Trial Site in Phase 1b/2 Acute Myeloid Leukemia (AML) Trial for PCM-075

    SAN DIEGO, Dec. 21, 2017 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a precision medicine biotechnology company, today announced the activation of the second clinical trial site for its Phase 1b/2 multicenter trial of PCM-075 in patients with AML, with Virginia Piper Cancer Institute and Principal Investigator, Dr. Michaela Tsai. The primary objectives of this Phase 1b/2 trial in AML are to evaluate the safety of PCM-075 in combination with either low-dose cytarabine or decitabine in subjects and to identify the maximum tolerated dose (MTD) in Phase 1b to administer to further evaluate the safety and preliminary efficacy in Phase 2. This trial is being led by Hematologist Jorge Eduardo Cortes, M.D., Deputy Department Chair, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center.

  • SmarterAnalyst4 months ago

    Why TrovaGene Inc (TROV) Stock Tanked 40% Today

    Shares of biotechnology company TrovaGene Inc (NASDAQ:TROV) are collapsing - down nearly 40% as of this writing. Each share of common stock is being sold together with a common warrant to purchase one share of common stock at a combined effective price to the public of $0.30 per share and accompanying common warrant. The common warrants will be exercisable immediately at an exercise price of $0.30 per share and will expire five years from the date of issuance. Added to its current 38.11 million shares outstanding, this offering promises to dilute existing shareholders by at least 40% -- coincidentally, about the same amount that the stock is down today.

  • Trovagene Prices $4.5 Million Public Offering
    PR Newswire4 months ago

    Trovagene Prices $4.5 Million Public Offering

    SAN DIEGO, Dec. 15, 2017 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a precision medicine biotechnology company, today announced the pricing of a public offering of 15,000,000 shares of its common stock (or common stock equivalents) and common warrants to purchase up to an aggregate of 15,000,000 shares of common stock. Each share of common stock (or common stock equivalent) is being sold together with a common warrant to purchase one share of common stock at a combined effective price to the public of $0.30 per share and accompanying common warrant.

  • Trovagene Submits Protocol to FDA for Phase 2 Clinical Trial of PCM-075 in Combination with Zytiga® for Metastatic Castration-Resistant Prostate Cancer
    PR Newswire4 months ago

    Trovagene Submits Protocol to FDA for Phase 2 Clinical Trial of PCM-075 in Combination with Zytiga® for Metastatic Castration-Resistant Prostate Cancer

    SAN DIEGO, Dec. 14, 2017 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a precision medicine biotechnology company, engaged in the development of targeted cancer therapies, today announced the filing of its protocol for a Phase 2 clinical trial of PCM-075 in combination with abiraterone acetate (Zytiga® - Johnson & Johnson), for metastatic Castration-Resistant Prostate Cancer (mCRPC) has been submitted to the U.S. Food and Drug Administration (FDA) for review. In this multi-center, open-label, Phase 2 trial, PCM-075 in combination with the standard dose of abiraterone and prednisone, all administered orally, will be evaluated for safety and efficacy.

  • Trovagene Announces the Launch of NextCollect™ Urine Collection and DNA Preservation Kit to Research Laboratories and Pharmaceutical Customers
    PR Newswire4 months ago

    Trovagene Announces the Launch of NextCollect™ Urine Collection and DNA Preservation Kit to Research Laboratories and Pharmaceutical Customers

    SAN DIEGO, Dec. 12, 2017 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a precision medicine biotechnology company, today announced that its proprietary NextCollect™ urine collection and DNA preservation kit is now available, for research use only, to clinical research laboratories and pharmaceutical customers.  NextCollect™ is being offered to both existing contracted clients and to new customers through an online ordering web distribution portal. NextCollect™ enables high-volume, non-invasive urine sample collection and isolation of DNA, and has the potential to expand the utility of nucleic acid testing from urine, including oncology, virology and infectious disease.

  • Trovagene Presents Data Showing Sensitivity of Triple Negative Breast Cancer (TNBC) Cell Lines to PCM-075 and Synergy with Zytiga® at San Antonio Breast Cancer Symposium (SABCS)
    PR Newswire4 months ago

    Trovagene Presents Data Showing Sensitivity of Triple Negative Breast Cancer (TNBC) Cell Lines to PCM-075 and Synergy with Zytiga® at San Antonio Breast Cancer Symposium (SABCS)

    Targeted treatment with highly selective Polo-like Kinase 1 inhibitor, PCM-075, may represent a new option in TNBC, particularly in combination with other abiraterone acetate SAN DIEGO , Dec. 7, 2017 /PRNewswire/ ...

  • Interested In TrovaGene Inc (TROV)? Here’s What Its Recent Track-Record Looks Like
    Simply Wall St.4 months ago

    Interested In TrovaGene Inc (TROV)? Here’s What Its Recent Track-Record Looks Like

    Investors with a long-term horizong may find it valuable to assess TrovaGene Inc’s (NASDAQ:TROV) earnings trend over time and against its industry benchmark as opposed to simply looking at aRead More...